To the Editor.
—In recent months, readers have noticed that Lederle Laboratories and Storz Ophthalmics Inc, in a joint effort, have begun placing zinc supplementation advertisements in the Archives and one other ophthalmologic journal, Retina. Earlier, the same two companies distributed tablet packets and advertising brochures to ophthalmologists nationwide. The information in those brochures was substantiated by several references, foremost of which was the article by Newsome et al1 in the February 1988 issue of the Archives.Review of that article reveals some data inconsistencies that the authors will not mind clarifying, I trust, even at this late time. In Table 5, they note that two eyes in the zinc-treated group sustained a visual loss of 20 letters or more, and that five eyes in the placebo group suffered the same loss. The first paragraph in the "Visual Acuity Outcomes" section reiterates that same data.In the next section,
Hawkins WR. Zinc Supplementation for Macular Degeneration. Arch Ophthalmol. 1991;109(10):1345. doi:10.1001/archopht.1991.01080100025012